ORAMED PHARMACEUTICALS INC. - FORM 10-K - EX-10.22 - LETTER AGREEMENT, DATED AS OF FEBRUARY 5, 2013, BETWEEN ORAMED PHARMACEUTICALS INC. AND REGALS CAPITAL LP. - November 25, 2016

Attached files

file filename
EX-10.32 - AMENDMENT TO THE AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT, DATED JULY 24, 2016, BETWEEN HEFEI TIANHUI INCUBATOR OF TECHNOLOGIES CO., LTD., ORAMED PHARMACEUTICALS, INC. AND ORAMED LTD. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxii_oramed.htm
EX-10.6 - AMENDMENT, DATED JUNE 27, 2016, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD., ENTERED INTO AS OF JULY 1, 2008, FOR THE SERVICES OF NADAV KIDRON. - ORAMED PHARMACEUTICALS INC.f10k2016ex10vi_oramed.htm
EX-23.1 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - ORAMED PHARMACEUTICALS INC.f10k2016ex23i_oramed.htm
EX-31.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex31i_oramed.htm
EX-32.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex32ii_oramed.htm
EX-32.1 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex32i_oramed.htm
EX-31.2 - CERTIFICATION - ORAMED PHARMACEUTICALS INC.f10k2016ex31ii_oramed.htm
EX-10.34 - GENERAL TECHNICAL AGREEMENT BETWEEN ORAMED LTD. AND PREMAS BIOTECH PVT. LTD., DATED JULY 24, 2016 - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxiv_oramed.htm
EX-10.33 - SERVICE AGREEMENT, DATED AS OF JUNE 3, 2016, BETWEEN ORAMED LTD. AND XERTECS GMBH - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxiii_oramed.htm
EX-10.31 - AMENDMENT TO THE AMENDED AND RESTATED TECHNOLOGY LICENSE AGREEMENT, DATED JUNE 3, 2016, BETWEEN HEFEI TIANHUI INCUBATOR OF TECHNOLOGIES CO., LTD., ORAMED PHARMACEUTICALS, INC. AND ORAMED LTD. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxxi_oramed.htm
EX-10.25 - AMENDMENT TO EMPLOYMENT AGREEMENT, DATED JUNE 27, 2016, BETWEEN ORAMED LTD. AND JOSHUA HEXTER. - ORAMED PHARMACEUTICALS INC.f10k2016ex10xxv_oramed.htm
EX-10.7 - AMENDMENT, DATED JUNE 27, 2016, TO CONSULTING AGREEMENTS BY AND BETWEEN ORAMED LTD. AND KNRY, LTD., ENTERED INTO AS OF JULY 1, 2008, FOR THE SERVICES OF MIRIAM KIDRON. - ORAMED PHARMACEUTICALS INC.f10k2016ex10vii_oramed.htm
10-K - ANNUAL REPORT - ORAMED PHARMACEUTICALS INC.f10k2016_oramedpharma.htm

Exhibit 10.22

 

 

February 5, 2013

 

David M. Slager

Regals Capital LP

152 West 57th Street

9th Floor

New York, NY 10019

 

Dear David:

 

This letter is to confirm certain undertakings that Oramed Pharmaceuticals Inc. (the "Company") has made in connection with your recent investment in the Company. The Company for ten years from October 26, 2012 on will not:

 

1.Grant stock options with an exercise price of less than $6.00 per share, as adjusted for stock splits and the like; or

 

2.Grant stock options to officers, directors, employees or consultants exercisable into more than 125,000 shares of common stock of the Company, in the aggregate per calendar year, without the consent of the top 3 non-founding shareholders (ie top 3 shareholders outside of Nadav Kidron and Dr. Miriam Kidron and other related parties).

 

Sincerely,

 

/s/ Nadav Kidron

 

Nadav Kidron, CEO

 

Oramed Pharmaceuticals, Inc.  |  2 Elza Street, Jerusalem, Israel 93706.  |  www.oramedpharma.com

Phone: 011 972-54-790 9058  |  Fax: 011 972-2-679 2336  |  Email: info@oramedpharma.com

Stock widget

Investing forum

ORAMED PHARMACEUTICALS INC. Reports